Marksans Pharma Limited — Investor Meet, 21-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Marksans Pharma reported strong Q2 FY26 results with operating revenue at Rs. 720.4 Cr (+12.2% YoY) and PAT at Rs. 99.1 Cr (+1.4% YoY). EBITDA margin improved sequentially to 20.1%. US market revenue grew robustly by 27%, fueled by new product launches. The UK business saw stability and new approvals. Management confirmed clarity on US pharma tariffs, easing prior uncertainties. They target Rs. 5,000 Cr revenue by FY30, with capacity expansion and new market entries in Europe like Germany. Working capital is normalizing, and full-year FY26 margins are expected north of 20%. The sentiment is positive, driven by clear strategic growth initiatives.